Pharmaceutical

Erasca trims workforce and pipeline to focus on KRAS and molecular glues

Erasca has made operational cuts while licensing a molecular glue therapy and a KRAS inhibitor for $22.5m upfront.

May 19, 2024 - 04:00
Erasca trims workforce and pipeline to focus on KRAS and molecular glues
Erasca has made operational cuts while licensing a molecular glue therapy and a KRAS inhibitor for $22.5m upfront.
Read the original article

Tags:

Previous Article

Sanders issues warning to Novo Nordisk amid GLP-1 drug price investigation

Next Article

Galapagos enters deal to boost decentralised CAR-T therapy production

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Bayer teams up with lncRNA-focused NextRNA in $547m deal

Bayer teams up with lncRNA-focused NextRNA in $547m deal

Aug 29, 2024

STAT+: Key Senate panel to consider PBM, drug pricing reform package

STAT+: Key Senate panel to consider PBM, drug pricing r...

Nov 3, 2023

PrEP therapies utter new hope in HIV preventive landscape as vaccine failures amass

PrEP therapies utter new hope in HIV preventive landsca...

Dec 1, 2024